Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

Gabriela Hobbs, MD, on Monitoring Adverse Events With Ponatinib

Posted: Monday, August 5, 2019

What is the best way for hematology teams to monitor patients being treated with ponatinib for CML and identify and manage toxicities as early as possible?



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.